How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Issues related to the civil rights of our employees, patients, and their families such as the Equality Act (HR 15, S 5).
Gabriella Miller Kids First Research Act 2.0
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2023 · second_quarter · Q2
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program.
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544).
Source: Senate LDA
PREVENT HPV Cancers Act of 2023
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544).
To amend title XVIII of the Social Security Act to provide coverage for wigs as durable medical equipment under the Medicare program, and for other purposes.
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544).
Support for LIFT the BAR Act (HR 4170, S 2038) which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
CONNECT for Health Act of 2023
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544).
Comprehensive Cancer Survivorship Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544).
Gabriella Miller Kids First Research Act 2.0
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544)
CONNECT for Health Act of 2023
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544).
LIFT the BAR Act of 2023
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support for LIFT the BAR Act (HR 4170, S 2038) which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
Energy and Water Development and Related Agencies Appropriations Act, 2024
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544).
Issues related to the civil rights of our employees, patients, and their families such as the Equality Act (HR 15, S 5).
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544).
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544)
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544).
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544)
VA Employee Fairness Act of 2021
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 5376, the Inflation Reduction Act, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
VA Employee Fairness Act of 2021
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 5376, the Inflation Reduction Act, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
VA Employee Fairness Act of 2021
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 5376, the Inflation Reduction Act, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
VA Employee Fairness Act of 2021
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
HEAL for Immigrant Families Act of 2021
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 5376, the Inflation Reduction Act, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
HEAL for Immigrant Families Act of 2021
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 5376, the Inflation Reduction Act, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
HEAL for Immigrant Families Act of 2021
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 5376, the Inflation Reduction Act, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
HEAL for Immigrant Families Act of 2021
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
Lymphedema Treatment Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access to care and therapeutics for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act; HR 5376, the Inflation Reduction Act and HR 3630/S 1315 Lymphedema Treatment Act.
Lymphedema Treatment Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access to care and therapeutics for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act; HR 5376, the Inflation Reduction Act and HR 3630/S 1315 Lymphedema Treatment Act.
Lymphedema Treatment Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access to care and therapeutics for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act; HR 5376, the Inflation Reduction Act and HR 3630/S 1315 Lymphedema Treatment Act.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Issues related to quality of life, survivorship and access for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Issues related to quality of life, survivorship and access to care and therapeutics for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act; HR 5376, the Inflation Reduction Act and HR 3630/S 1315 Lymphedema Treatment Act.
Issues related to quality of life, survivorship and access to care and therapeutics for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act; HR 5376, the Inflation Reduction Act and HR 3630/S 1315 Lymphedema Treatment Act.
Issues related to quality of life, survivorship and access to care and therapeutics for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act; HR 5376, the Inflation Reduction Act and HR 3630/S 1315 Lymphedema Treatment Act.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Issues related to the civil rights of our employees, patients, and their families such as HR5 / S393 - the Equality Act;
Issues related to the civil rights of our employees, patients, and their families such as HR5 / S393 - the Equality Act;
Issues related to the civil rights of our employees, patients, and their families such as HR5 / S393 - the Equality Act;
Issues related to the civil rights of our employees, patients, and their families such as HR5 / S393 - the Equality Act;
DIVERSE Trials Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
DIVERSE Trials Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
DIVERSE Trials Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
DIVERSE Trials Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act
LIFT the BAR Act of 2021
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to access to critical health and social services for lawfully present immigrant families such as HR 5227, the Lift the Bar Act and Public Charge regulations.
LIFT the BAR Act of 2021
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to access to critical health and social services for lawfully present immigrant families such as HR 5227, the Lift the Bar Act and Public Charge regulations.
LIFT the BAR Act of 2021
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to access to critical health and social services for lawfully present immigrant families such as HR 5227, the Lift the Bar Act and Public Charge regulations.
Inflation Reduction Act of 2022
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access to care and therapeutics for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act; HR 5376, the Inflation Reduction Act and HR 3630/S 1315 Lymphedema Treatment Act.
Inflation Reduction Act of 2022
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access to care and therapeutics for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act; HR 5376, the Inflation Reduction Act and HR 3630/S 1315 Lymphedema Treatment Act.
Inflation Reduction Act of 2022
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 5376, the Inflation Reduction Act, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
Inflation Reduction Act of 2022
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access to care and therapeutics for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act; HR 5376, the Inflation Reduction Act and HR 3630/S 1315 Lymphedema Treatment Act.
Inflation Reduction Act of 2022
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 5376, the Inflation Reduction Act, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
Inflation Reduction Act of 2022
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Funding related to biomedical and cancer research and innovation at the NIH and NCI in the Labor, Health and Human Services, Education bill; Tobacco control policies in the Agriculture, Rural Development, FDA & Related Agencies appropriations bill funding for ARPA-H; HR 5376, Build Back Better Act-include policies related to the establishment of ARPA-H, lymphedema treatment access, palliative care and telemedicine; FY 2023 Funding for a potential Therapeutic Food Pantry project at DFCI.
Inflation Reduction Act of 2022
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Funding related to biomedical and cancer research and innovation at the NIH and NCI including the omnibus appropriation for Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022; funding for the NIH,NCI and ARPA-H;HR 5376, Build Back Better Act-include policies related to the establishment of ARPA-H, lymphedema treatment access, palliative care and telemedicine; FY 2023 Funding for the NIH and NCI and a potential Therapeutic Food Pantry project at DFCI.
Inflation Reduction Act of 2022
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 5376, the Inflation Reduction Act, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act
Gabriella Miller Kids First Research Act 2.0
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Gabriella Miller Kids First Research Act 2.0
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Gabriella Miller Kids First Research Act 2.0
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act
Gabriella Miller Kids First Research Act 2.0
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Lymphedema Treatment Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access to care and therapeutics for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act; HR 5376, the Inflation Reduction Act and HR 3630/S 1315 Lymphedema Treatment Act.
Lymphedema Treatment Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access to care and therapeutics for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act; HR 5376, the Inflation Reduction Act and HR 3630/S 1315 Lymphedema Treatment Act.
Lymphedema Treatment Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access to care and therapeutics for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act; HR 5376, the Inflation Reduction Act and HR 3630/S 1315 Lymphedema Treatment Act.
CONNECT for Health Act of 2021
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 5376, the Inflation Reduction Act, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
CONNECT for Health Act of 2021
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
CONNECT for Health Act of 2021
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 5376, the Inflation Reduction Act, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
CONNECT for Health Act of 2021
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access to care and therapeutics for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act; HR 5376, the Inflation Reduction Act and HR 3630/S 1315 Lymphedema Treatment Act.
CONNECT for Health Act of 2021
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 5376, the Inflation Reduction Act, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
CONNECT for Health Act of 2021
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
CONNECT for Health Act of 2021
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access to care and therapeutics for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act; HR 5376, the Inflation Reduction Act and HR 3630/S 1315 Lymphedema Treatment Act.
CONNECT for Health Act of 2021
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access to care and therapeutics for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act; HR 5376, the Inflation Reduction Act and HR 3630/S 1315 Lymphedema Treatment Act.
Gabriella Miller Kids First Research Act 2.0
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Gabriella Miller Kids First Research Act 2.0
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Gabriella Miller Kids First Research Act 2.0
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Gabriella Miller Kids First Research Act 2.0
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
HEAL for Immigrant Families Act of 2021
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 5376, the Inflation Reduction Act, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
HEAL for Immigrant Families Act of 2021
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 5376, the Inflation Reduction Act, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
HEAL for Immigrant Families Act of 2021
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 5376, the Inflation Reduction Act, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
HEAL for Immigrant Families Act of 2021
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
Issues related to quality of life, survivorship and access for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Issues related to quality of life, survivorship and access to care and therapeutics for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act; HR 5376, the Inflation Reduction Act and HR 3630/S 1315 Lymphedema Treatment Act.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Issues related to quality of life, survivorship and access to care and therapeutics for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act; HR 5376, the Inflation Reduction Act and HR 3630/S 1315 Lymphedema Treatment Act.
Issues related to quality of life, survivorship and access to care and therapeutics for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act; HR 5376, the Inflation Reduction Act and HR 3630/S 1315 Lymphedema Treatment Act.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bill; FY 2024 Funding for a potential Therapeutic Food Pantry project and freezers for research labs at DFCI.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544)
Issues related to the civil rights of our employees, patients, and their families such as the Equality Act (HR 15, S 5).
Support for LIFT the BAR Act (HR 4170, S 2038) which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Science & Technology Policy (OSTP), SENATE
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2023 · first_quarter · 1A
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bill; FY 2024 Funding for a potential Therapeutic Food Pantry project and freezers for research labs at DFCI.
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act, a bill to provide coverage for wigs as durable medical equipment under the Medicare program, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including the Connect for Health Act among other telehealth bills.
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality; prior authorization in the Medicare program.
Support for the LIFT the BAR Act which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
Issues related to the civil rights of our employees, patients, and their families such as the Equality Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Science & Technology Policy (OSTP), SENATE
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2023 · first_quarter · Q1
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bill; FY 2024 Funding for a potential Therapeutic Food Pantry project and freezers for research labs at DFCI.
Issues related to the civil rights of our employees, patients, and their families such as the Equality Act
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act, a bill to provide coverage for wigs as durable medical equipment under the Medicare program, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including the Connect for Health Act among other telehealth bills.
Support for the LIFT the BAR Act which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality; prior authorization in the Medicare program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Science & Technology Policy (OSTP), SENATE
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2022 · fourth_quarter · Q4
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Issues related to access to critical health and social services for lawfully present immigrant families such as HR 5227, the Lift the Bar Act and Public Charge regulations.
Issues related to the civil rights of our employees, patients, and their families such as HR5 / S393 - the Equality Act;
Issues related to quality of life, survivorship and access to care and therapeutics for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act; HR 5376, the Inflation Reduction Act and HR 3630/S 1315 Lymphedema Treatment Act.
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 5376, the Inflation Reduction Act, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for ARPA-H in the Labor, Health and Human Services, Education bill; Tobacco control policies in the Agriculture, Rural Development, FDA & Related Agencies appropriations bill;
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Science & Technology Policy (OSTP), SENATE
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2022 · third_quarter · 3A
Issues related to the civil rights of our employees, patients, and their families such as HR5 / S393 - the Equality Act;
Issues related to quality of life, survivorship and access to care and therapeutics for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act; HR 5376, the Inflation Reduction Act and HR 3630/S 1315 Lymphedema Treatment Act.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Issues related to access to critical health and social services for lawfully present immigrant families such as HR 5227, the Lift the Bar Act and Public Charge regulations.
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for ARPA-H in the Labor, Health and Human Services, Education bill; Tobacco control policies in the Agriculture, Rural Development, FDA & Related Agencies appropriations bill; FY 2023 Funding for a potential Therapeutic Food Pantry project at DFCI.
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 5376, the Inflation Reduction Act, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Science & Technology Policy (OSTP), SENATE
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2022 · third_quarter · Q3
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for ARPA-H in the Labor, Health and Human Services, Education bill; Tobacco control policies in the Agriculture, Rural Development, FDA & Related Agencies appropriations bill; FY 2023 Funding for a potential Therapeutic Food Pantry project at DFCI.
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2022 · second_quarter · Q2
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act
Issues related to the civil rights of our employees, patients, and their families such as HR5 / S393 - the Equality Act;
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2022 · first_quarter · Q1
Funding related to biomedical and cancer research and innovation at the NIH and NCI including the omnibus appropriation for Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022; funding for the NIH,NCI and ARPA-H;HR 5376, Build Back Better Act-include policies related to the establishment of ARPA-H, lymphedema treatment access, palliative care and telemedicine; FY 2023 Funding for the NIH and NCI and a potential Therapeutic Food Pantry project at DFCI.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 5376, the Inflation Reduction Act, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
Issues related to access to critical health and social services for lawfully present immigrant families such as HR 5227, the Lift the Bar Act and Public Charge regulations.
Issues related to the civil rights of our employees, patients, and their families such as HR5 / S393 - the Equality Act;
Issues related to quality of life, survivorship and access to care and therapeutics for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act; HR 5376, the Inflation Reduction Act and HR 3630/S 1315 Lymphedema Treatment Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Science & Technology Policy (OSTP), SENATE
Funding related to biomedical and cancer research and innovation at the NIH and NCI in the Labor, Health and Human Services, Education bill; Tobacco control policies in the Agriculture, Rural Development, FDA & Related Agencies appropriations bill funding for ARPA-H; HR 5376, Build Back Better Act-include policies related to the establishment of ARPA-H, lymphedema treatment access, palliative care and telemedicine; FY 2023 Funding for a potential Therapeutic Food Pantry project at DFCI.
Issues related to quality of life, survivorship and access for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE